Fact Sheet

Financial Aid for Macular Degeneration Medications

Learn about financial aid resources that may be available to help cover the costs of your macular degeneration prescription medications.

Macular Degeneration Medications

(On mobile devices, swipe left to see all of the table columns.)

Medication NameGenericDrug CompanyToll-Free Number
Eylea™AfliberceptRegeneron1-855-EYLEA-4U
Lucentis®RanibizumabGenentech1-866-4-ACCESS
Macugen®

Pegaptanib Sodium

Eyetech1-866-272-8838
Visudyne®VerteporfinNovartis1-800-245-5356

 

Financial Aid Helpful Resources

(On mobile devices, swipe left to see all of the table columns.)

OrganizationProgramPhone Number
Partnership for Prescription AssistancePrescription Assistance Service1-888-477-2669
TogetherONETogether Rx Access1-800-444-4106
RxHopePatient Assistance Programs1-877-267-0517
MAP InternationalMedical Supply Program

1-800-225-8550

MedicarePrescription Drug Plans1-800-633-4227

 

 

This content was first posted on: July 5, 2015

The information provided is a public service of the BrightFocus Foundation and is not intended to constitute medical advice. It should not in any way substitute for the advice of a qualified healthcare professional. Please consult your physician for personalized medical advice; all medications and supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical product or therapy.

More Like This

  • Fact Sheet

    Clinical Trial Information for Macular Degeneration

    It can take many years for a potential treatment for macular degeneration to work its way from the laboratory, through rigorous testing and, finally, to become approved by the U.S. Food and Drug Administration (FDA). Learn more about the process and how clinical trials work.

    April 15, 2016
  • Fact Sheet

    Macular Degeneration: Frequently Asked Questions

    Age-related macular degeneration (AMD) is a common eye disease that causes deterioration of the macula, the central area of the retina. Read the answers to the most frequently asked questions about this eye disease.

    March 1, 2016
Don't miss out.
Receive research updates, inspiring stories, and expert advice
Keep me informed about: *
Please select at least one.
You must select at least one disease category.
Please enter your first name.
Please enter your last name.